2.9000
-0.0400
(-1.36%)
At close: January 10 at 4:00:00 PM EST
2.8300
-0.07
(-2.41%)
After hours: January 10 at 6:32:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
6,785.0000
7,492.0000
17,651.0000
32,881.0000
30,210.0000
Operating Income
-6,785.0000
-7,492.0000
-17,651.0000
-32,881.0000
-30,210.0000
Net Non Operating Interest Income Expense
245.0000
364.0000
275.0000
519.0000
1,161.0000
Other Income Expense
--
216.0000
-490.0000
-105.0000
278.0000
Pretax Income
-6,324.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Net Income Common Stockholders
-6,324.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Diluted NI Available to Com Stockholders
-6,324.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Basic EPS
69.72
-30.00
-127.80
-237.60
-243.00
Diluted EPS
69.72
-30.00
-127.80
-237.60
-243.00
Basic Average Shares
258.1340
230.7940
139.6810
136.6530
118.2260
Diluted Average Shares
258.1340
230.7940
139.6810
136.6530
118.2260
Total Operating Income as Reported
--
-7,492.0000
-17,651.0000
-32,881.0000
-30,210.0000
Rent Expense Supplemental
--
261.0000
401.0000
530.0000
430.0000
Total Expenses
6,785.0000
7,492.0000
17,651.0000
32,881.0000
30,210.0000
Net Income from Continuing & Discontinued Operation
-6,324.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Normalized Income
-6,540.0000
-7,128.0000
-17,376.0000
-32,362.0000
-29,049.0000
Interest Income
--
375.0000
297.0000
562.0000
1,192.0000
Net Interest Income
245.0000
364.0000
275.0000
519.0000
1,161.0000
EBIT
-6,785.0000
-7,492.0000
-17,651.0000
-32,881.0000
-30,210.0000
EBITDA
-6,696.0000
-7,461.0000
-17,616.0000
-32,839.0000
-30,171.0000
Reconciled Depreciation
89.0000
31.0000
35.0000
42.0000
39.0000
Net Income from Continuing Operation Net Minority Interest
-6,324.0000
-6,912.0000
-17,866.0000
-32,467.0000
-28,771.0000
Total Unusual Items Excluding Goodwill
216.0000
216.0000
-490.0000
-105.0000
278.0000
Total Unusual Items
216.0000
216.0000
-490.0000
-105.0000
278.0000
Normalized EBITDA
-6,912.0000
-7,677.0000
-17,126.0000
-32,734.0000
-30,449.0000
12/31/2020 - 3/13/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PRTG Portage Biotech Inc.
4.3700
-7.22%
GLYC GlycoMimetics, Inc.
0.2650
-4.26%
CLGN CollPlant Biotechnologies Ltd.
4.1983
-5.87%
SNGX Soligenix, Inc.
3.2000
-2.14%
ADIL Adial Pharmaceuticals, Inc.
1.0200
-0.97%
RLMD Relmada Therapeutics, Inc.
0.4124
-8.76%
QNRX Quoin Pharmaceuticals, Ltd.
0.6215
-0.26%
SEELQ Seelos Therapeutics, Inc.
0.3900
0.00%
BOLD Boundless Bio, Inc.
2.4200
-3.20%
GNPX Genprex, Inc.
0.7800
-3.26%